UMIN-CTR Clinical Trial

Unique ID issued by UMIN C000000426
Receipt number R000000517
Scientific Title A randomized trial to evaluate the cardioprotective effect of the uric acid-lowering therapy for hyperuricemia in patients with chronic heart failure
Date of disclosure of the study information 2006/06/01
Last modified on 2022/02/19 10:43:55

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A randomized trial to evaluate the cardioprotective effect of the uric acid-lowering therapy for hyperuricemia in patients with chronic heart failure

Acronym

A randomized trial to evaluate the cardioprotective effect of uric acid-lowering therapy for hyperuricemia in patients with chronic heart failure

Scientific Title

A randomized trial to evaluate the cardioprotective effect of the uric acid-lowering therapy for hyperuricemia in patients with chronic heart failure

Scientific Title:Acronym

A randomized trial to evaluate the cardioprotective effect of uric acid-lowering therapy for hyperuricemia in patients with chronic heart failure

Region

Japan


Condition

Condition

Hyperuricemia in patients with chronic heart failure

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the cardioprotective effect of uric acid-lowering therapy for hyperuricemia in patients with chronic heart failure by comparing between benzbromarone, allopurinol and life-style modification treatments.

Basic objectives2

Pharmacodynamics

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

1) The plasma BNP levels
2) The plasma levels of markers of oxidative stress
3) The plasma levels of pro-inflammatory cytokines

Key secondary outcomes

1) NYHA functional class
2) Hospitalizaion for worsening heart failure


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -but assessor(s) are blinded

Control

No treatment

Stratification

NO

Dynamic allocation

NO

Institution consideration


Blocking

YES

Concealment

No need to know


Intervention

No. of arms

3

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Benzbromarone (25-75 mg daily) for 4 months

Interventions/Control_2

Allopurinol (100-300mg daily) for 4 months

Interventions/Control_3

Life-style modification

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

The patients who have stable left ventricular systolic dysfunction (fractional shortening <25%) and hyperuricemia (serum uric acid >=8.0 mg/dl)

Key exclusion criteria

1) Gouty arthritis or tophus
2) Patients who have already taken the uric acid-lowering drugs
3) Renal dysfunction (serum creatinin >=2.0 mg/dl)
4) Urinary or renal calculus
5) Hepatic dysfunction (GPT (ALT) >=50 IU/l)
6) Patients who do not agree and whom physician judges inappropriate to this trial for any reason

Target sample size

60


Research contact person

Name of lead principal investigator

1st name Masafumi
Middle name
Last name Kitakaze

Organization

National Cardiovascular Center

Division name

Cardiovascular Division

Zip code

565-8565

Address

5-7-1 Fujishirodai, Suita City, Osaka Pref. 565-8565, JAPAN

TEL

06-6833-5012

Email

asamasa@xd5.so-net.ne.jp


Public contact

Name of contact person

1st name Masanori
Middle name
Last name Asakura

Organization

National Cardiovascular Center

Division name

Cardiovascular Clinical Research Center

Zip code

565-8565

Address

5-7-1 Fujishirodai, Suita City, Osaka Pref. 565-8565, JAPAN

TEL

06-6833-5012

Homepage URL


Email

asamasa@xd5.so-net.ne.jp


Sponsor or person

Institute

National Cardiovascular Center

Institute

Department

Personal name



Funding Source

Organization

Japan Cardiovascular Research Foundation

Organization

Division

Category of Funding Organization

Non profit foundation

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

National Cardiovascular Center

Address

5-7-1 Fujishirodai, Suita City, Osaka Pref. 565-8565, JAPAN

Tel

06-6833-5012

Email

kitakaze@zf6.so-net.ne.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2006 Year 06 Month 01 Day


Related information

URL releasing protocol

https://pubmed.ncbi.nlm.nih.gov/29507373/

Publication of results

Published


Result

URL related to results and publications

https://pubmed.ncbi.nlm.nih.gov/29507373/

Number of participants that the trial has enrolled

213

Results

We found that the estimated and actual occurrence possibility of cardiovascular events were well linked.

Results date posted

2022 Year 02 Month 19 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

patients hospitalized due to acute HF

Participant flow

We prospectively enrolled 213 patients with ADHF admitted between May 2013 and March 2015 in three different hospitals of National Cerebral and Cardiovascular Center (n = 114) and Hokkaido (n = 80) and Kyushu Universities (n = 19) and followed up these patients until the time of cardiovascular events or the end of April 2016.

Adverse events

cardiovascular events

Outcome measures

the time of cardiovascular events

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2006 Year 01 Month 23 Day

Date of IRB

2006 Year 06 Month 01 Day

Anticipated trial start date

2006 Year 06 Month 01 Day

Last follow-up date

2007 Year 05 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2006 Year 06 Month 01 Day

Last modified on

2022 Year 02 Month 19 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000517


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name